AMGEN INC — Director's Dealing 2022

May 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2022-05-02

Reporting Person: Gordon Murdo (EVP Global Commercial Ops)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-02	Common Stock	A	4330	—	Acquired	49195	Direct
2022-05-03	Common Stock	F	808	$230.92	Disposed	48387	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-02	Nqso (Right to Buy)	$230.92	A	35352	Acquired	2032-05-02	Common Stock (35352)	Direct

Footnotes

F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

F2: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,534 RSUs which vest in one installment of 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 494 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.